Freshly Printed - allow 7 days lead
Couldn't load pickup availability
Quality by Design for Biopharmaceuticals
Principles and Case Studies
Anurag S. Rathore (Edited by), AS Rathore (Author), Rohin Mhatre (Edited by)
9780470282335, Wiley
Hardback, published 10 July 2009
328 pages
24.1 x 16 x 1.9 cm, 0.585 kg
The concepts, applications, and practical issues of Quality by Design Quality by Design (QbD) is a new framework currently being implemented by the FDA, as well as EU and Japanese regulatory agencies, to ensure better understanding of the process so as to yield a consistent and high-quality pharmaceutical product. QbD breaks from past approaches in assuming that drug quality cannot be tested into products; rather, it must be built into every step of the product creation process. Quality by Design: Perspectives and Case Studies presents the first systematic approach to QbD in the biotech industry. A comprehensive resource, it combines an in-depth explanation of basic concepts with real-life case studies that illustrate the practical aspects of QbD implementation. In this single source, leading authorities from the biotechnology industry and the FDA discuss such topics as: Filled with vivid case studies that illustrate QbD at work in companies today, Quality by Design is a core reference for scientists in the biopharmaceutical industry, regulatory agencies, and students.
Foreword xiii Preface xv Preface to the Wiley Series on Biotechnology and Related Topics xvii Contributors xix 1 QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS 1 1.1 Introduction 1 1.2 Critical Quality Attributes 2 1.3 An Overview of Design Space 3 1.4 Raw Materials and their Impact on QbD 4 1.5 Process Analytical Technology 4 1.6 The Utility of Design Space and QbD 5 1.7 Conclusions 7 2 CONSIDERATIONS FOR BIOTECHNOLOGY PRODUCT QUALITY BY DESIGN 9 2.1 Introduction 9 2.2 Quality by Design 10 2.3 Relevant Product Attributes 11 2.4 Manufacturing Process 14 2.5 Developing a Design Space 18 2.6 Uncertainty and Complexity 22 2.7 Future Horizons 23 2.8 QbD Submission Thoughts 25 2.9 Implementation Plans 26 2.10 Summary 27 3 MOLECULAR DESIGN OF RECOMBINANT MALARIA VACCINES EXPRESSED BY Pichia pastoris 31 3.1 Introduction 31 3.2 The Malaria Genome and Proteome 34 3.3 Expression of Two Malaria Antigens in P. pastoris 34 3.4 Summary 46 4 USING A RISK ASSESSMENT PROCESS TO DETERMINE CRITICALITY OF PRODUCT QUALITY ATTRIBUTES 53 4.1 Introduction 53 4.2 Examples of Criticality Determination 60 4.3 Conclusion 81 5 CASE STUDY ON DEFINITION OF PROCESS DESIGN SPACE FOR A MICROBIAL FERMENTATION STEP 85 5.1 Introduction 85 5.2 Approach Toward Process Characterization 87 5.3 Risk Analysis 88 5.4 Small-Scale Model Development and Qualification 89 5.5 Design of Experiment Studies 94 5.6 Worst Case Studies 96 5.7 Definition of Design Space 99 5.8 Definition of Validation Acceptance Limits 103 5.9 Regulatory Filing, Process Monitoring, and Postapproval Changes 106 6 APPLICATION OF QbD PRINCIPLES TO TANGENTIAL FLOW FILTRATION OPERATIONS 111 6.1 Introduction 111 6.2 Applications of TFF in Biotechnology 113 6.3 Tangential Flow Filtration Operating Principles 113 6.4 TFF Design Objectives 115 6.5 Membrane Selection 115 6.6 TFF Operating Parameter Design 118 6.7 TFF Diafiltration Operating Mode Design 122 6.8 Summary 125 7 APPLICATIONS OF DESIGN SPACE FOR BIOPHARMACEUTICAL PURIFICATION PROCESSES 127 7.1 Introduction 127 7.2 Establishing Design Space for Purification Processes during Process Development 128 7.3 Applications of Design Space 131 7.4 Cell Harvest and Product Capture Steps 131 7.5 Protein A Capture Column 136 7.6 Hydrophobic Interaction Chromatography 137 7.7 Anion Exchange Chromatography 138 7.8 Summary 141 8 VIRAL CLEARANCE: A STRATEGY FOR QUALITY BY DESIGN AND THE DESIGN SPACE 143 8.1 Introduction 143 8.2 Current and Future Approaches to Virus Clearance Characterization 143 8.3 Benefits of Applying Design Space Principles to Virus Clearance 144 8.4 Technical Limitations Related to Adoption of QdB/Design Space Concepts in Virus Clearance 145 8.5 Developing a Virus Clearance Design Space 148 8.6 Staying in the Design Space 156 8.7 Conclusion 157 9 APPLICATION OF QUALITY BY DESIGN AND RISK ASSESSMENT PRINCIPLES FOR THE DEVELOPMENT OF FORMULATION DESIGN SPACE 161 9.1 Introduction 161 9.2 Quality by Design (QbD) Approach 162 9.3 Target Product Profile (TPP) 163 9.4 Molecular Degradation Characterization 164 9.5 Active Pharmaceutical Ingredient (API) Critical Properties 166 9.6 Preformulation Characterization 167 9.7 Initial Formulation Risk Assessments 168 9.8 Formulation Optimization and Design Space 169 9.9 Selection of Solution Formulation Composition 171 9.10 Summary 173 10 APPLICATION OF QbD PRINCIPLES TO BIOLOGICS PRODUCT: FORMULATION AND PROCESS DEVELOPMENT 175 10.1 Introduction: QbD in Biologics Product Development 175 10.2 Risk Assessment Process 177 10.3 Examples 178 10.4 Conclusions 191 11 QbD FOR RAW MATERIALS 193 11.1 Introduction 193 11.2 Background 194 11.3 Current Practice for Raw Materials 195 11.4 QbD in Development 195 11.5 QbD in manufacturing 196 11.6 QbD for organizations 197 11.7 Tests Available 197 11.8 Conclusions and Future Prospects 207 12 PAT TOOLS FOR BIOLOGICS: CONSIDERATIONS AND CHALLENGES 211 12.1 Introduction 211 12.2 Cell Culture and Fermentation PAT Tools 214 12.3 Purification PAT Tools 223 12.4 Formulation PAT Tools 228 12.5 PAT Tools for Bioprocess Starting Materials, Defined Media, and Complex Raw Materials 230 12.6 Chemometrics and Advanced Process Control Tools 232 12.7 The power of PLS and PCA 233 12.8 "Relevant Time"Column Integrity Monitoring (Moments Analysis versus HETP) 240 12.9 Challenges for Implementation of PAT Tools 244 12.10 Future PAT Tools 247 13 EVOLUTION AND INTEGRATION OF QUALITY BY DESIGN AND PROCESS ANALYTICAL TECHNOLOGY 255 13.1 Introduction 255 13.2 Evolution of PAT and Quality by Design (QbD): Emerging Guidelines and Standards 256 13.3 Process Analytical Technology (PAT) 261 13.4 Quality by Design 263 13.5 Implementing QbD and PAT 266 13.6 Conclusions 282 Acknowledgments 283 References 283 Index 287
Rohin Mhatre and Anurag S. Rathore
Steven Kozlowski and Patrick Swann
David L. Narum
Mark A Schenerman, Milton J. Axley, Cynthia N. Oliver, Kripa Ram, and Gail F. Wasserman
Pim van Hoek, Jean Harms, Xiangyang Wang, and Anurag S. Rathore
Peter K. Watler and John Rozembersky
Douglas J. Cecchini
Gail Sofer and Jeffrey Carter
Kingman Ng and Natarajan Rajagopalan
Satish K. Singh, Carol F. Kirchhoff, and Amit Banerjee
Maureen Lanan
Michael Molony and Cenk Undey
Duncan Low and Joseph Phillips
Subject Areas: Biology, life sciences [PS]
